

IMJM

INTERNATIONAL MEDICAL JOURNAL MALAYSIA

VOLUME 15 | SUPPLEMENT ISSUE

DECEMBER 2016

Medical Research Symposium &
Pacific Partnership in conjunction with

Kuantan Research Day 2016

International Research Network : The Way Forward

ABSTRACTS

Organized by :



**Kulliyah of Medicine, IIUM
Research Management Centre, Kuantan**

In collaboration:



Basic Health Sciences

Oral

Abstract ID: 34

Epigenetic methylation status of P16, MGMT and SPOCK2 in diffuse Large B cell lymphoma

Lailatul Jalilah^a | Aziah Ismail^b | Norlelawati A. Talib^c | Naznin Muhammad^c | Faezahtul Arbaeyah Hussain^d | Norafiza Zainuddin^a

^aDepartment of Biomedical Science, Kulliyah of Allied Health Sciences, International Islamic University Malaysia

^bInstitute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia

^cDepartment of Pathology and Laboratory Medicine, Kulliyah of Medicine, International Islamic University Malaysia

^dDepartment of Pathology, School of Medical Sciences, Universiti Sains Malaysia

Introduction: Epigenetic methylation has been implicated in the pathogenesis of diffuse large B cell lymphoma (DLBCL). This study investigated the methylation status of *p16*, *MGMT* and *SPOCK2*. Aberrantly methylated *p16* and *MGMT* have been linked to DLBCL, but not *SPOCK2*. *p16* inhibits cyclin-dependent kinase, which results in retinoblastoma phosphorylation and blockage of cell cycle at G1 phase. *MGMT* removes alkyl adduct at O⁶-guanine, thus preventing lethal cross-links. *SPOCK2*, an extracellular chondroitin and heparin sulfate proteoglycans, abolishes the inhibition of membrane-type 1-matrix metalloproteinase which might enhance the angiogenesis. The absence of *SPOCK2* methylation was therefore hypothesized in the majority of cases in this study. **Methods:** Extracted DNA from 88 formalin-fixed paraffin-embedded (FFPE) tissues of DLBCL were subjected to bisulfite conversion followed by methylation-specific PCR (MSP) analysis for *p16*, *MGMT* and *SPOCK2* methylation. *p16* methylation was also quantified in 16 samples through pyrosequencing assay. **Results:** *p16* methylation was observed in 65/88 (74%) samples by MSP. Pyrosequencing detected *p16* methylation in all 16 samples ranging from 18% to 81%. *MGMT* methylation was detected in all 88 (100%) cases. Methylated *SPOCK2* was found in 83 (94.3%) samples. There was a significant association between *p16* methylation status with patients above 50 years of age ($p= 0.04$). **Conclusions:** These preliminary discoveries may serve as a good platform in order to gain a comprehensive overview on the epigenetics contribution in the pathogenesis of DLBCL. Pyrosequencing is a robust tool in detecting and quantifying methylation.

KEYWORDS: DLBCL, epigenetics, MSP, pyrosequencing